Sign in
CHMMF Stock Price, Chart, Stats & News
Chimeric Therapeutics Limited
Save
Chimeric Therapeutics Limited (CHMMF) does not currently pay a dividend.
4.10M
Market cap
–
Current P/E
–
Forward P/E
CHMMF chart
1M
3M
1Y
5Y
Loading chart...
About
Health care
Sector
Biotechnology
Industry
Chimeric Therapeutics Limited is an Australian biotechnology firm operating at the clinical stage, dedicated to advancing and commercializing a diverse portfolio of cell-based treatments specifically for cancer. Its pipeline features several promising candidates. CHM 0201, utilizing a core natural killer (NK) cell platform, is currently undergoing Phase I clinical trials for the treatment of both solid tumors and hematological malignancies.
Similar securities
Based on sector and market capitalization
Report issue